Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of the Vascular Disrupting Agent NPI-2358 in Combination With Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer

NCT00630110 is registered in ClinicalTrials.gov with Nereus Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00630110
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00630110 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of the Vascular Disrupting Agent NPI-2358 in Combination With Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer
Lead sponsor
Nereus Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
February 29, 2008
Completion date
June 30, 2011
Enrollment
172 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

cancer